BioRestorative Therapies, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$360K
Cost of Revenue
$24K
Gross Profit
$336K
R&D
$10M
D&A
$210K
Operating Income
$-16M
EBITDA
$-15M
Interest Expense
—
Other Income/Expense
$1M
Pretax Income
$-14M
Tax Provision
—
Net Income
$-14M
Gross Margin
93.4%
Operating Margin
-4350.1%
Net Margin
-3959.4%
Effective Tax Rate
—
Deferred Tax Assets
—
DTA Valuation Allowance
$23M
Tax Credit Carryforwards
$330K
NOL Carryforwards
$20M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost
$174K
Revenue YoY Variation
-10.3%
Income YoY Variation
-35.4%